GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MiNK Therapeutics Inc (NAS:INKT) » Definitions » Cash Ratio

MiNK Therapeutics (MiNK Therapeutics) Cash Ratio : 0.52 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is MiNK Therapeutics Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. MiNK Therapeutics's Cash Ratio for the quarter that ended in Mar. 2024 was 0.52.

MiNK Therapeutics has a Cash Ratio of 0.52. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for MiNK Therapeutics's Cash Ratio or its related term are showing as below:

INKT' s Cash Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.78   Max: 2.36
Current: 0.52

During the past 5 years, MiNK Therapeutics's highest Cash Ratio was 2.36. The lowest was 0.01. And the median was 0.78.

INKT's Cash Ratio is ranked worse than
82.18% of 1470 companies
in the Biotechnology industry
Industry Median: 3.065 vs INKT: 0.52

MiNK Therapeutics Cash Ratio Historical Data

The historical data trend for MiNK Therapeutics's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MiNK Therapeutics Cash Ratio Chart

MiNK Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
0.04 0.19 2.36 1.55 0.30

MiNK Therapeutics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.32 0.93 0.62 0.30 0.52

Competitive Comparison of MiNK Therapeutics's Cash Ratio

For the Biotechnology subindustry, MiNK Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MiNK Therapeutics's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MiNK Therapeutics's Cash Ratio distribution charts can be found below:

* The bar in red indicates where MiNK Therapeutics's Cash Ratio falls into.



MiNK Therapeutics Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

MiNK Therapeutics's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=3.367/11.403
=0.30

MiNK Therapeutics's Cash Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash Ratio (Q: Mar. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=5.817/11.108
=0.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MiNK Therapeutics  (NAS:INKT) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


MiNK Therapeutics Cash Ratio Related Terms

Thank you for viewing the detailed overview of MiNK Therapeutics's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


MiNK Therapeutics (MiNK Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T cell therapies to treat cancer and other life-threatening illnesses.
Executives
Agenus Inc 10 percent owner 3 FORBES ROAD, LEXINGTON MA 02421
Garo H Armen director 3 FORBES ROAD, LEXINGTON MA 02421
Ulf Wiinberg director
Brian Corvese director C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010
Christine M Klaskin officer: Treasurer 3 FORBES ROAD, LEXINGTON MA 02421
Jennifer Buell director, officer: See Remarks 3 FORBES ROAD, LEXINGTON MA 02421
Barbara Ryan director 22 CAVRAY ROAD, NORWALK CT 06855
Walter Md Flamenbaum director 3 FORBES ROAD, LEXINGTON MA 02421
John Baldoni director 3 FORBES ROAD, LEXINGTON MA 02421
Peter Behner director 3 FORBES ROAD, LEXINGTON MA 02421
Van Dijk Marcus Antonius officer: Chief Technology Officer 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010